Real-World Data of Triplet Combination of Trastuzumab, Lapatinib, and Chemotherapy in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study-Reference-Cited by-同舟云学术

Real-World Data of Triplet Combination of Trastuzumab, Lapatinib, and Chemotherapy in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study

Published:2020-03-03 Issue: Volume:10 Page:
ISSN:2234-943X
Container-title:Frontiers in Oncology
language:
Short-container-title:Front. Oncol.

Author:

Li Yi,Gong Chengcheng,Lu Qianyi,Zhou Zhaochun,Luo Ting,Li Wei,Li Gang,Ge Rui,Xu Fei,Wang Biyun

Funder

National Natural Science Foundation of China

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference25 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018

2. Breast cancer treatment: a review;Waks;JAMA,2019

3. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;N Engl J Med,2001

4. HER-2-positive breast cancer: hope beyond trastuzumab;Bartsch;Biodrugs,2007

5. HER2 therapy: molecular mechanisms of trastuzumab resistance;Nahta;Breast Cancer Res.,2006

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tyrosine kinase inhibitors in HER2‐positive metastatic breast cancer with trastuzumab emtansine resistance: insights from a multicenter retrospective real‐world study;MedComm;2024-06-19

2. Role of the Tumor Microenvironment in Mediating Resistance to Anti-HER2 Antibodies;Critical Reviews™ in Oncogenesis;2024

3. A nationwide observational study in heavily pretreated metastatic HER2-positive breast cancer patients;Acta Oncologica;2023-02-01

4. HER2-positive metastatic breast cancer with brain metastases responds favorably to pyrotinib and trastuzumab-based treatment: A case report and literature review;Frontiers in Oncology;2023-01-19

5. Systemic investigation of inetetamab in combination with small molecules to treat HER2-overexpressing breast and gastric cancers;Open Life Sciences;2023-01-01